Bouclet, Florian
Calleja, Anne
Dilhuydy, Marie-Sarah
Véronèse, Lauren
Pereira, Bruno
Amorim, Sandy
Cymbalista, Florence
Herbaux, Charles
de Guibert, Sophie
Roos-Weil, Damien
Hivert, Bénédicte
Aurran, Thérèse
Dupuis, Jehan
Blouet, Anaise
Tchernonog, Emmanuelle
Laribi, Kamel
Dmytruck, Nataliya
Morel, Pierre
Michallet, Anne-Sophie
Dartigeas, Caroline
Tournilhac, Olivier
Nguyen-Khac, Florence
Delmer, Alain
Feugier, Pierre
Ysebaert, Loïc
Guièze, Romain
Funding for this research was provided by:
AbbVie
Article History
Received: 15 July 2020
Accepted: 11 January 2021
First Online: 25 January 2021
Compliance with ethical standards
:
: Bouclet Florian: AbbVie, AmgenHerbaux Charles: research funding: Takeda, AbbVie; honoraria and non-financial support: Roche, Janssen-Cilag, AbbVie, Takedade Guibert Sophie: honoraria: AbbVie, Janssen, GileadHivert Bénedicte: participation boards scientifiques: Sanofi, JanssenAurran Thérèse: honoraria: Janssen, AbbVieDupuis Jehan: Celgene and AbbVieLaribi Kamel: scientific partnership: Novartis, Takeda, Janssen, Sandoz, AbbVie, Amgen, RocheMichallet Anne-Sophie: scientific partnership: Janssen AbbVieDartigeas Caroline: honoraria and travels support: AbbVie, Roche. Travel support: JanssenTournilhac Olivier: Roche Gilead Amgen AbbVie Takeda SandozDelmer Alain: advisory board: Janssen, Astra Zeneca, Roche, AbbVie. Travel support: Janssen, AbbVie, Roche, GileadFeugier Pierre: Janssen, Roche, Gilead, Amgen, AstraZeneca, AbbVieYsebaert Loic: advisory boards: AbbVie, Astra Zeneca, Gilead, Janssen, RocheGuieze Romain: advisory board: Astra Zeneca, Janssen, AbbVie. Travel support: Roche, AbbVie, Gilead, JansenThere is no conflict of interest to disclose for the remaining authors.
: The study was approved by the board of the FILO and was conducted according to the Declaration of Helsinki.
: All the authors approved the final manuscript.
: Not applicable.